Pharmacokinetics of Antibiotics in Patients With Cystic Fibrosis Trated With Elexacaftor/Tezacaftor/Ivacaftor (ETI) (PKCF)
Cystic fibrosis (CF) is associated with major pharmacokinetic and pharmacodynamic alterations affecting antibiotic exposure, including changes in absorption, distribution, metabolism, and elimination. Historically, these alterations justified the use of higher antibiotic doses in CF patients in order to achieve therapeutic concentrations and improve pulmonary outcomes.
The advent of highly effective CFTR modulators, particularly the triple combination elexacaftor/tezacaftor/ivacaftor (ETI), has substantially improved pulmonary function, nutritional status, inflammatory burden, and quality of life in patients with CF. ETI therapy also appears to modify respiratory microbiology and reduce the frequency of pulmonary exacerbations.
These clinical and physiological improvements may alter antibiotic pharmacokinetics and pharmacodynamics in patients with CF, potentially making current high-dose antibiotic recommendations less appropriate for some patients. Since repeated exposure to high-dose antibiotics is associated with cumulative toxicities, particularly aminoglycoside-related ototoxicity and nephrotoxicity, reassessment of antibiotic dosing strategies is warranted.
The PKCF study is a multicenter, prospective, observational, non-interventional study designed to characterize the pharmacokinetic profiles of intravenous antibiotics administered during pulmonary exacerbations in adolescents and adults with cystic fibrosis receiving ETI therapy.
연구 개요
상세 설명
Patients with cystic fibrosis experience substantial physiological changes that affect the pharmacokinetics of medications, including antibiotics. Altered gastrointestinal absorption, increased volume of distribution, enhanced renal clearance, chronic systemic inflammation, and modified protein binding have historically led to recommendations for increased antibiotic dosing in CF patients.
Additionally, thick airway mucus, biofilm formation, high bacterial inoculum, and chronic airway infection contribute to altered antibiotic pharmacodynamics and reduced antibiotic efficacy.
Highly effective CFTR modulators, particularly elexacaftor/tezacaftor/ivacaftor (ETI), have profoundly changed the clinical course of cystic fibrosis by improving lung function, reducing pulmonary exacerbations, improving nutritional status, and modifying airway microbiology. These changes may normalize or partially normalize antibiotic pharmacokinetics and pharmacodynamics.
However, evidence regarding the impact of ETI therapy on antibiotic pharmacokinetics remains extremely limited. To date, only one retrospective pediatric study has evaluated the effect of CFTR modulators on intravenous tobramycin pharmacokinetics during pulmonary exacerbations.
The PKCF study aims to prospectively evaluate plasma antibiotic concentrations and pharmacokinetic parameters in CF patients receiving ETI during pulmonary exacerbations requiring antibiotic therapy. Antibiotic concentrations will be compared with established PK/PD targets according to current national recommendations.
The study may contribute to future optimization of antibiotic dosing strategies in patients with CF treated with ETI, while minimizing toxicity and supporting antimicrobial stewardship.
연구 유형
등록 (추정된)
연락처 및 위치
연구 연락처
- 이름: Matthieu Pichelin
- 이메일: matthieu.pichelin@ildys.org
연구 연락처 백업
- 이름: Marion Buyse, PharmD, PhD
- 전화번호: +33298293447
- 이메일: marion.buyse@ildys.org
연구 장소
-
-
-
Roscoff, 프랑스, 29680
- 모병
- Fondation Ildys
-
연락하다:
- Marion Buyse, PharmD; PhD
- 전화번호: 0298293447
- 이메일: marion.buyse@ildys.org
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 어린이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- Diagnosis of cystic fibrosis confirmed by sweat test and/or genetic testing
- Treatment with elexacaftor/tezacaftor/ivacaftor (ETI) for at least 3 months
- Age 12 years or older
- Patient informed and not objecting to participation; for minors, parents/legal guardians informed and not objecting to participation
- Clinical indication for antibiotic therapy for pulmonary exacerbation or respiratory infection according to treating physician
- Affiliation to a social security system
Exclusion Criteria:
- Lung transplantation or heart-lung transplantation
- Patients under guardianship or curatorship
- Pregnant or breastfeeding women
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
Patients with cystic fibrosis treated with ETI receiving antibiotic therapy
Patients with cystic fibrosis treated with ETI receiving antibiotic therapy for pulmonary exacerbation
|
Routine antibiotic therapy and therapeutic drug monitoring are performed according to standard clinical practice
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Pharmacokinetic profiles of antibiotics during pulmonary exacerbation treatment
기간: Day 3 of antibiotic therapy
|
Plasma antibiotic concentrations will be measured at Day 3 of treatment to determine pharmacokinetic parameters including:
Pharmacokinetic/pharmacodynamic ratios will be evaluated according to bacterial minimum inhibitory concentrations (MICs):
|
Day 3 of antibiotic therapy
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Clinical efficacy: body weight evolution
기간: Baseline, Day 3, Day 7-10, and end of antibiotic treatment
|
the Clinical parameters body weight in kilograms
|
Baseline, Day 3, Day 7-10, and end of antibiotic treatment
|
|
Clinical efficacy: temperature evolution
기간: Baseline, Day 3, Day 7-10, and end of antibiotic treatment
|
the Clinical parameters temperature in celsius degree
|
Baseline, Day 3, Day 7-10, and end of antibiotic treatment
|
|
Clinical efficacy: appetite evolution
기간: Baseline, Day 3, Day 7-10, and end of antibiotic treatment
|
the Clinical parameters "appetite" will be score on a scale from 0 to 10 with higher score mean worse outcome
|
Baseline, Day 3, Day 7-10, and end of antibiotic treatment
|
|
Clinical efficacy: fatigue evolution
기간: Baseline, Day 3, Day 7-10, and end of antibiotic treatment
|
the Clinical parameters "fatigue" will be score on a scale from 0 to 10 with higher score mean worse outcome
|
Baseline, Day 3, Day 7-10, and end of antibiotic treatment
|
|
Clinical efficacy: dyspnea evolution
기간: Baseline, Day 3, Day 7-10, and end of antibiotic treatment
|
the Clinical parameters "dyspnea" will be score on a scale from 0 to 10 with higher score mean worse outcome
|
Baseline, Day 3, Day 7-10, and end of antibiotic treatment
|
|
Clinical efficacy: sputum volume
기간: Baseline, Day 3, Day 7-10, and end of antibiotic treatment
|
the Clinical parameters "sputum volume" will be score on a scale from 0 to 10 with higher score mean worse outcome
|
Baseline, Day 3, Day 7-10, and end of antibiotic treatment
|
|
Clinical efficacy: sputum purulence
기간: Baseline, Day 3, Day 7-10, and end of antibiotic treatment
|
the Clinical parameters "sputum purulence" will be score on a scale from 0 to 10 with higher score mean worse outcome
|
Baseline, Day 3, Day 7-10, and end of antibiotic treatment
|
|
biological evolution: Renal function evolution
기간: Baseline, Day 3, and end of antibiotic treatment
|
renal function will be evaluated by measuring plasma creatinine and calculated glomerular filtration rate
|
Baseline, Day 3, and end of antibiotic treatment
|
|
biological evolution: inflammatory markers
기간: Baseline, Day 3, and end of antibiotic treatment
|
inflammation will be evaluated by measuring plasma c protein reactive and plasma leukocytes concentration
|
Baseline, Day 3, and end of antibiotic treatment
|
|
Treatment adherence
기간: through study completion, an average 14 days
|
Treatment adherence will be evaluated by the ratio of antibiotic doses administered to doses prescribed
|
through study completion, an average 14 days
|
|
number of participants with treatment-related adverse events
기간: through study completion, an average 14 days
|
Adverse events related to antibiotic therapy will be collected and graded according to NCI CTCAE version 6.0
|
through study completion, an average 14 days
|
공동 작업자 및 조사자
스폰서
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- RI2025-016
- 2025-A02333-46 (기타 식별자: IDRCB Number)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .